Blog

Blog

Drug Target Encyclopedia Series (1) — CD20

Linkedin

Release Time：

2025-11-13 14:22

CD20 is a transmembrane phosphoprotein expressed on the surface of B cells from the pre-B to mature B-cell stage, making it a critical target in B-cell malignancies and autoimmune diseases. While its precise function remains under investigation, CD20 is believed to play a role in B-cell activation, proliferation, and calcium signaling. Importantly, it is absent on hematopoietic stem cells and plasma cells, making it an ideal target for selective B-cell depletion without affecting long-term immune regeneration. 

CD20-targeted therapies have revolutionized the treatment of B-cell malignancies, such as non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Monoclonal antibodies (mAbs) against CD20, such as rituximab (Rituxan), obinutuzumab (Gazyva), and ofatumumab (Arzerra), work by inducing antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and direct apoptosis in B cells. These therapies have significantly improved survival rates in patients with B-cell cancers. 

Beyond oncology, CD20-targeting has also been transformative in autoimmune diseases. Anti-CD20 therapies are widely used to treat conditions like multiple sclerosis (MS), rheumatoid arthritis (RA), and systemic lupus erythematosus (SLE) by selectively depleting pathogenic B cells while preserving other components of the immune system. 

New therapeutic approaches, such as bispecific antibodies and antibody-drug conjugates (ADCs), are being developed to further enhance CD20-targeted treatments. Ongoing research aims to refine these therapies to improve efficacy, reduce resistance, and minimize adverse effects, ensuring better patient outcomes in both oncology and autoimmune diseases. 

Need CD20 for drug discovery? 

Fill out the form below, or visit the link: to browse the complete list of available in-stock products.  

Prev

Drug Target Encyclopedia Series (2) — BCMA

No

Next